Skip Navigation


JAC Advance Access originally published online on May 18, 2004
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
54/1/193    most recent
dkh261v2
dkh261v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lanao, J. M.
Right arrow Articles by Domínguez-Gil, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lanao, J. M.
Right arrow Articles by Domínguez-Gil, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy 2004 54(1):193-198; doi:10.1093/jac/dkh261
JAC vol.54 no.1 © The British Society for Antimicrobial Chemotherapy 2004; all rights reserved.

Pharmacokinetic basis for the use of extended interval dosage regimens of gentamicin in neonates

José M. Lanao1,*, Ma Victoria Calvo2, José Antonio Mesa2, Ana Martín-Suárez1, Ma Teresa Carbajosa3, Francisco Miguelez1 and Alfonso Domínguez-Gil1,2

Departments of 1 Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, and 2 Pharmacy Service; 3 Neonatology Unit, Pediatrics Service, University Hospital, University of Salamanca, Salamanca, Spain

* Corresponding author. Tel: +34-923-294536; Fax: +34-923-294515; Email: jmlanao{at}usal.es

Objectives: To analyse the pharmacokinetic basis for the use of extended-interval dosage regimens of gentamicin in neonates using population pharmacokinetics.

Patients and methods: The population pharmacokinetics of gentamicin was studied retrospectively in a population of 113 neonates divided into two groups: one for computing the population model (n=97) and another for validation (n=36). A one-compartment pharmacokinetic model and non-linear mixed-effects modelling were used to assess the population pharmacokinetic model.

Results: Weight (W) and postnatal age (PA) were the covariates that influenced the pharmacokinetic parameters of gentamicin. The final population model obtained was: distribution volume, V (L)=0.636 x W (kg)0.852; clearance, Cl (L/h)=0.032 x W (kg)1.482+0.0024 x PA (days). The predictive performance of the model in the population validation was adequate for clinical purposes. The optimized population model allowed us to simulate gentamicin serum levels and their variability, in this kind of patient, when extended-interval dosage administration regimens were implemented.

Conclusions: According to our pharmacokinetic population model, initial doses of gentamicin of 10 mg/kg, and dosage intervals between 36–48 h, appear to be appropriate to achieve target peak and trough serum levels of 15–20 and <0.5 mg/L, respectively, when extended-interval dosage regimens are implemented in newborns. The half-life of gentamicin in premature babies of very low weight and gestational age <31 weeks is long. Thus, to achieve serum concentrations in the 1–10 mg/L range, the use of dosage regimens of 5 mg/kg at 36–48 h dosage intervals seems suitable.

Keywords: population pharmacokinetics , extended-interval dosage regimens , aminoglycosides


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.